Approved Covid antiviral VV116 shows promising early results against Nipah in new study Approved Covid antiviral VV116 shows promising early results against Nipah in new study
TUESDAY, FEBRUARY 03, 2026
A study in Emerging Microbes & Infections reports that VV116—an oral antiviral already approved for Covid-19 treatment in China and Uzbekistan—strongly inhibited Nipah virus strains in the lab and improved survival in hamster models, raising hopes for faster treatment options if further research confirms benefits in people.